12 documents found, page 1 of 2
Umbilical-Cord-Derived Mesenchymal Stromal Cells Modulate 26 Out of 41 T Cell S...
Laranjeira, Paula; Dos Santos, Francisco; Salvador, Maria João; Simões, Irina N.; Cardoso, Carla M. P.; Silva, Bárbara M.; Henriques-Antunes, HelenaSystemic sclerosis (SSc) is an immune-mediated disease wherein T cells are particularly implicated, presenting a poor prognosis and limited therapeutic options. Thus, mesenchymal-stem/stromal-cell (MSC)-based therapies can be of great benefit to SSc patients given their immunomodulatory, anti-fibrotic, and pro-angiogenic potential, which is associated with low toxicity. In this study, peripheral blood mononucle...
Reply to 'Imbalance of threat and soothing systems in fibromyalgia: rephrasing ...
Pinto, Ana M.; Geenen, Rinie; Wager, Tor D.; Lumley, Mark A.; Häuser, Winfried; Kosek, Eva; Ablin, Jacob N.; Amris, Kirstine; Branco, Jaime
Development of prediction models to select older RA patients with comorbidities...
Hartman, Linda; Silva, José A. P. da; Buttgereit, Frank; Cutolo, Maurizio; Opris-Belinski, Daniela; Szekanecz, Zoltan; Masaryk, PavolObjective: To develop prediction models for individual patient harm and benefit outcomes in elderly patients with RA and comorbidities treated with chronic low-dose glucocorticoid therapy or placebo. Methods: In the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) study, 451 RA patients 65 years of age were randomized to 2 years 5 mg/day prednisolone or placebo. Eight prediction models were deve...
Reply to: Hypothetical model ignores many important pathophysiologic mechanisms...
Pinto, Ana M.; Geenen, Rinie; Wager, Tor D.; Häuser, Winfried; Kosek, Eva; Ablin, Jacob N.; Amris, Kirstine; Branco, Jaime; Buskila, Dan
Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: ...
Ferreira, Ricardo J. O.; Welsing, Paco M. J.; Jacobs, Johannes Wg; Gossec, Laure; Ndosi, Mwidimi; Machado, Pedro; van der Heijde, Désirée
Patient Experienced Symptom State in rheumatoid arthritis: sensitivity to chang...
Duarte, Catiá; Kvien, Tore K.; Sexton, Joe; Santos, Eduardo; de Wit, Maarten; Gossec, Laure; Silva, José A. P. daObjectives. The Patient Experienced Symptom State (PESS) is a single-question, patient-reported outcome that is validated to assess global disease impact in RA. This study addresses its sensitivity to change, and reliability. Methods. Disease activity, disease impact in the seven domains of RA Impact of Disease (RAID) and PESS were assessed in patients with RA from the NOR-DMARD registry, at two visits, 6 month...
Prevalence of healthy aging among community dwelling adults age 70 and older fr...
Schietzel, Simeon; Chocano-Bedoya, Patricia O; Sadlon, Angelique; Gagesch, Michael; Willett, Walter C; Orav, Endel J; Kressig, Reto W; Vellas, BrunoBackground: To compare the prevalence of healthy aging among adults age 70 and older from 5 European countries recruited for the DO-HEALTH clinical trial. Participants were selected for absence of prior major health events. Methods: Cross-sectional analysis of DO-HEALTH baseline data. All 2,157 participants (mean age 74.9, SD 4.4; 61.7% women) were included and 2,123 had data for all domains of the healthy agin...
Editorial: Osteoporosis in Rheumatic Diseases, What's New?
Ruaro, Barbara; Guiducci, Serena; Silva, José A. P. da; Wade, Barbara; Baratella, Elisa; Confalonieri, Marco
SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID ...
Saadoun, David; Vieira, Matheus; Vautier, Mathieu; Baraliakos, Xenofon; Andreica, Ioana; Silva, José A. P. da; Sousa, Marlene; Luís, MarianaBackground The COVID-19 pandemic has raised numerous questions among patients with immune-mediated inflammatory diseases regarding potential reciprocal effects of COVID-19 and their underlying disease, and potential effects of immunomodulatory therapy on outcomes related to COVID-19. The seroprevalence of SARS-CoV-2 and factors associated with symptomatic COVID-19 in patients with immune-mediated inflammatory d...
Do we need bone mineral density to estimate osteoporotic fracture risk? A 10-ye...
Marques, Andréa; Lucas, Raquel; Simões, Eugénia; Verstappen, Suzanne M. M.; Jacobs, Johannes W. G.; Silva, José A. P. daObjective E valuate the performance of FRAX®, with and without bone mineral densitometry (BMD), in predicting the occurrence of fragility fractures over 10 years. Methods Participants aged ≥40 years at baseline, with a complete set of data and a minimum of 8.5 years of follow-up were identified from three cohorts (n=2626). Ten-year fracture risk at baseline were estimated with FRAX® and assessed by comparison w...